Yi-yang Hu

1200 Cailun Road
Pudong, 201203, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Drug Development for MASH-Related Compensated Cirrhosis: Past, Present and Future.

Drug Development for MASH-Related Compensated Cirrhosis: Past, Present and Future.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: April 01, 2026

Beyond BMI: Reassessing the Prevalence of Obesity in Patients With MASLD Under the Lancet Commission Diagnostic Criteria.

Beyond BMI: Reassessing the Prevalence of Obesity in Patients With MASLD Under the Lancet Commission Diagnostic Criteria.

Journal: Diabetes, obesity & metabolism

Published: February 21, 2026

Serum Biomarker Identification of Damp-Heat Pattern in Patients with Chronic Liver Diseases.

Serum Biomarker Identification of Damp-Heat Pattern in Patients with Chronic Liver Diseases.

Journal: Chinese journal of integrative medicine

Published: October 29, 2025

The CGA combination enhances bile acids alternative biosynthesis pathway and alleviates MASH induced by methionine-choline-deficient diet.

The CGA combination enhances bile acids alternative biosynthesis pathway and alleviates MASH induced by methionine-choline-deficient diet.

Journal: The Journal of pharmacy and pharmacology

Published: July 26, 2025

Sanren Decoction Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Protecting Mitochondrial Function.

Sanren Decoction Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Protecting Mitochondrial Function.

Journal: Chinese journal of integrative medicine

Published: June 06, 2025

Persistent Binge Drinking History Associated With Advanced Liver Fibrosis and All-Cause Mortality in MetALD.

Persistent Binge Drinking History Associated With Advanced Liver Fibrosis and All-Cause Mortality in MetALD.

Journal: Alimentary pharmacology & therapeutics

Published: May 22, 2025

Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis.

Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis.

Journal: Metabolism: clinical and experimental

Published: August 20, 2024

A Novel Score Based on Controlled Attenuation Parameter Accurately Predicts Hepatic Steatosis in Individuals With Metabolic Dysfunction Associated Steatotic Liver Disease: A Derivation and Independent Validation Study.

A Novel Score Based on Controlled Attenuation Parameter Accurately Predicts Hepatic Steatosis in Individuals With Metabolic Dysfunction Associated Steatotic Liver Disease: A Derivation and Independent Validation Study.

Journal: Clinical and translational gastroenterology

Published: August 21, 2023

USP5: Comprehensive insights into structure, function, biological and disease-related implications, and emerging therapeutic opportunities.

USP5: Comprehensive insights into structure, function, biological and disease-related implications, and emerging therapeutic opportunities.

Journal: Molecular and cellular probes

Published: July 27, 2023

A high-trans fat, high-carbohydrate, high-cholesterol, high-cholate diet-induced nonalcoholic steatohepatitis mouse model and its hepatic immune response.

A high-trans fat, high-carbohydrate, high-cholesterol, high-cholate diet-induced nonalcoholic steatohepatitis mouse model and its hepatic immune response.

Journal: Nutrition & metabolism

Published: October 20, 2022

Amelioration of Non-Alcoholic Steatohepatitis by Atractylodes macrocephala Polysaccharide, Chlorogenic Acid, and Geniposide Combination Is Associated With Reducing Endotoxin Gut Leakage.

Amelioration of Non-Alcoholic Steatohepatitis by Atractylodes macrocephala Polysaccharide, Chlorogenic Acid, and Geniposide Combination Is Associated With Reducing Endotoxin Gut Leakage.

Journal: Frontiers in cellular and infection microbiology

Published: December 02, 2021

Geniposide and Chlorogenic Acid Combination Improves Non-Alcoholic Fatty Liver Disease Involving the Potent Suppression of Elevated Hepatic SCD-1.

Geniposide and Chlorogenic Acid Combination Improves Non-Alcoholic Fatty Liver Disease Involving the Potent Suppression of Elevated Hepatic SCD-1.

Journal: Frontiers in pharmacology

Published: January 14, 2021

Showing 1-12 of 51

Last Updated: 09/26/2026